BAY2701250

BAY2701250 is an investigational protein-based therapeutic being developed by Bayer for the treatment of pulmonary hypertension, particularly pulmonary hypertension due to left heart disease within the broader category of pulmonary heart disease.[1][3][9] It is being evaluated in a first-in-human, randomized, single-blind, placebo-controlled Phase 1 study in healthy male volunteers to characterize safety, tolerability, pharmacokinetics, and pharmacodynamics after single-dose intravenous infusion or subcutaneous administration.[1][3][9] The precise molecular target, signaling pathway, and mechanism of action have not been publicly disclosed, and no efficacy data or regulatory designations are yet available.[1][3]